LivaNova reports Q4 adjusted EPS 87c, consensus 77c

Reports Q4 revenue $310.1M, consensus $287.39M. “We delivered strong revenue growth in both the fourth quarter and full year,” said Bill Kozy, Interim CEO and Board Chair of LivaNova. “Our 2023 performance reflects double-digit revenue growth across all regions, an improvement in adjusted operating margin and a 17% increase in adjusted diluted earnings per share. We are pleased with these financial outcomes as well as the progress made in refining the business strategy and portfolio. As we enter 2024 with this strategic focus, we are excited to welcome Vlad Makatsaria as LivaNova’s next CEO. Under his leadership, I have great confidence that LivaNova will build on these results and achieve our commitments to serving patients while creating shareholder value.”